PFE — PFIZER INC catalysts
Next verified catalyst
2026-07-13 — A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in · official source ↗
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-07-13 in 21d
ESTIMATED |
READOUT
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevromet
Phase 3 · Metastatic Castrate Resistant Prostate Cancer (mCRPC) |
PFE PFIZER INC | PF-06821497, Docetaxel, Enzalutamide |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-07-30 in 1mo
ESTIMATED |
READOUT
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatr
Phase 3 · COVID-19 |
PFE PFIZER INC | nirmatrelvir, ritonavir |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-08-23 in 2mo
ESTIMATED |
READOUT
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination Wit
Phase 1/2 · Breast Cancer, Solid Tumors |
PFE PFIZER INC | PF-07220060 + PF-07104091 combination do |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-08-30 in 2mo
ESTIMATED |
READOUT
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in P
Phase 3 · Multiple Myeloma |
PFE PFIZER INC | Elranatamab, Elotuzumab, Pomalidomide, D |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-08-31 in 2mo
ESTIMATED |
READOUT
A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults
Phase 3 · Respiratory Syncytial Virus (RSV) |
PFE PFIZER INC | RSVpreF |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-09-01 in 2mo
ESTIMATED |
READOUT
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given
Phase 1/2 · Breast Cancer |
PFE PFIZER INC | ARV-471, Abemaciclib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-09-02 in 2mo
ESTIMATED |
READOUT
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult Pe
Phase 1/2 · Pulmonary Arterial Hypertension |
PFE PFIZER INC | PF-07868489 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-09-15 in 3mo
ESTIMATED |
READOUT
A Study of MET233 in Combination With MET097 in Individuals With Obesity or Over
Phase 1/2 · Obesity and Obesity-related Medical Conditions |
PFE PFIZER INC | MET233 and MET097, MET097 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-09-23 in 3mo
ESTIMATED |
READOUT
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Ad
Phase 2 · Liposarcoma, Prostate Cancer |
PFE PFIZER INC | PF-07220060, Letrozole, Fulvestrant, Mid |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-10-08 in 4mo
ESTIMATED |
READOUT
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With
Phase 3 · Migraine |
PFE PFIZER INC | Rimegepant |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|
| 2026-10-19 in 4mo
ESTIMATED |
READOUT
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In Peop
Phase 2 · Atopic Dermatitis |
PFE PFIZER INC | PF-07275315, PF-07264660 |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|